We are live on ! Find out more
DRNA

Dicerna Pharmaceuticals
DRNA

Delisted

DRNA was delisted on the 27th of December, 2021.

55 hedge funds and large institutions have $80.2M invested in Dicerna Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2.91% less ownership

Funds ownership: 75.41% → 72.5% (-2.9%)

5% less funds holding

Funds holding: 58 → 55 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

61% less capital inflows, than outflows

Capital inflows: $2.63M | Capital outflows: $6.73M

Holders
55
Holders Change
-3
Holders Change %
-5.17%
% of All Funds
1.46%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
4
Increased
19
Reduced
17
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

DRNA Hedge Fund Activity: Q1 2016 in Review

55 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals (DRNA) for Q1 2016, worth a combined $80.2M — down 57% from $185M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of DRNA and 4 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 19 added.

The largest buyer was Oxford Asset Management, adding an estimated $759K. The largest seller was Wellington Management Group, cutting an estimated $2.3M.

  • 55 institutional investors held Dicerna Pharmaceuticals (DRNA) as of Q1 2016, down from 58 in Q4 2015.
  • Funds reported $80.2M of Dicerna Pharmaceuticals stock for Q1 2016, down 57% quarter-over-quarter.
  • 4 funds opened new Dicerna Pharmaceuticals positions in Q1 2016 and 7 closed out, a net change of -3 holders.
  • The largest Dicerna Pharmaceuticals buyer in Q1 2016 was Oxford Asset Management, an estimated $759K added.
  • The largest Dicerna Pharmaceuticals seller in Q1 2016 was Wellington Management Group, an estimated $2.3M sold.

Based on aggregated 13F filings for Q1 2016.